HRS2014: Boston Scientific’s S-ICD strong at 22 months, promising in post-ICD patients
Conference coverage
HRS2014: Medtronic cardiac rhythm implants fail 1st in head-to-head studies of longevity, researchers say
HRS2014: Boston Scientific’s S-ICD causes few complications
Boston Scientific’s (NYSE:BSX) lead-free S-ICD cardiac rhythm management made another strong showing, with results from an analysis of more than 880 patients showing relatively few complications.
HRS2014: Devices combat drugs for treatment of AF stroke-risk patients
New clinical data continues to suggest that left atrial appendage occlusion devices may pose an improvement over warfarin drug regimens for treating patients at increased risk of stroke, researchers reported today.
HRS14: St. Jude’s quadripolar pacing wins in 1st head-to-head study
The view from HRS 2014: This week at the Heart Rhythm Society’s 35th Annual Scientific Sessions
Things are still pretty quiet on opening day of Heart Rhythm 2014, the Heart Rhythm Society’s 35th Annual Scientific Sessions in semi-sunny San Francisco, but the week is shaping up to be a busy one.
There are few major announcements expected from this year’s sessions, but attendees are looking forward to some important updates on key new technologies and trends in cardiac pacing and electrophysiology, coming from the biggest players in the market.
ACC14: The quickening pace of change
I just returned from the American College of Cardiology and wanted to write down a few of my 50,000-foot impressions from the meeting for, as the song goes, the times, they are a-changin’.
ACC 2014: Conflicts in renal denervation, competition in valves
The American College of Cardiology’s annual Scientific Sessions are regularly a source of controversy and competition, but medtech titan Medtronic’s (NYSE:MDT) highly anticipated renal denervation study results may have been the most confounding.
J.P. Morgan medtech wrap-up: Ups and downs from San Francisco
NuVasive soars on estimates for Q4 and 2014
California medical device maker NuVasive Inc. (NSDQ:NUVA) is flying high today after raising its revenue projections for 2013 amid higher-than-expected 4th quarter sales.
Intuitive Surgical CEO responds to hubbub over adverse events
